Among the clinically available drugs, nilotinib, acalabrutinib, and fostamatinib block Lyn, CSNK2A1, and SYK proteins, which were the most represented in our analysis of AML cell–derived EVs. This evidence concerns the gene LYN and acute myeloid leukemia.